List of Atelvia drug patents

Atelvia is owned by Apil.

Atelvia contains Risedronate Sodium.

Atelvia has a total of 3 drug patents out of which 0 drug patents have expired.

Atelvia was authorised for market use on 08 October, 2010.

Atelvia is available in tablet, delayed release;oral dosage forms.

Atelvia can be used as treatment of osteoporosis in postmenopausal women.

The generics of Atelvia are possible to be released after 09 January, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246989 APIL Dosage forms of bisphosphonates
Jan, 2026

(2 years from now)

US7645460 APIL Dosage forms of risedronate
Jan, 2028

(4 years from now)

US7645459 APIL Dosage forms of bisphosphonates
Jan, 2028

(4 years from now)

Drugs and Companies using RISEDRONATE SODIUM ingredient

Market Authorisation Date: 08 October, 2010

Treatment: Treatment of osteoporosis in postmenopausal women

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of ATELVIA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic